The Controller and PAO of Ultragenyx (NASDAQ: RARE) is Selling Shares

By Carrie Williams

Today, the Controller and PAO of Ultragenyx (NASDAQ: RARE), Theodore Alan Huizenga, sold shares of RARE for $215.8K.

In addition to Theodore Alan Huizenga, 9 other RARE executives reported Sell trades in the last month. Following Theodore Alan Huizenga’s last RARE Sell transaction on March 02, 2017, the stock climbed by 0.5%.

Based on Ultragenyx’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $5,000 and GAAP net loss of $71.29 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $55.22 million. The company has a one year high of $91.35 and a one year low of $46.52. Currently, Ultragenyx has an average volume of 263.4K.

Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $99.00, reflecting a -13.2% downside.

The insider sentiment on Ultragenyx has been positive according to 51 insider trades in the past three months. This sentiment is higher than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ultragenyx Pharmaceutical, Inc. is a clinical-stage biotechnology company that is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. It intends to build therapies to address these clinically underserved diseases. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.